Brain Metastases News and Research

RSS

ASTRO creates guideline on radiotherapeutic, surgical management for brain metastases

The American Society for Radiation Oncology (ASTRO) has developed a guideline on the radiotherapeutic and surgical management for newly diagnosed brain metastases. It has been published in Practical Radiation Oncology (PRO), ASTRO's official clinical practice journal.

9 Feb 2012

PEDF may suppress brain from tumor-induced damage, metastasis

Scientists are one step closer to repairing the damage caused by brain metastasis, a major challenge in cancer treatment, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

4 Jan 2012

JHN to initiate new Phase I immunotherapy trial in glioblastoma

Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.

15 Dec 2011

Geron commences GRN1005 Phase 2 trial in breast cancer

Geron Corporation today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases - Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from breast cancer.

13 Dec 2011

HER2-positive metastatic breast cancer women benefit from trastuzumab and chemotherapy

The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed.

18 Jul 2011

NewYork-Presbyterian Hospital offers two new treatment options for cancer patients

NewYork-Presbyterian Hospital has two new treatment options for patients with brain tumors and other cancers -- a next-generation radiosurgical Gamma Knife and linear accelerator.

From Elekta 11 Jul 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

Bristol-Myers Squibb to present abstracts on oncology compounds at ASCO 2011 Annual Meeting

Bristol-Myers Squibb Company, a leading global BioPharma company in oncology, today announced that more than 95 scientific abstracts on its approved and investigational oncology compounds will be featured at the 47th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 3-7.

21 May 2011

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

Study finds Gamma Knife procedure effective for brain metastases treatment

The volume of normal brain tissue exposed to radiation during treatment for multiple metastases appears to depend on which stereotactic radiosurgery system is employed, according to a recent study in the Journal of Neurosurgery.

31 Mar 2011

AACR to honor UNC scientist with $181,000 grant for breast cancer research

The American Association for Cancer Research announced today that Carey Anders, MD, assistant professor of medicine and a member of UNC Lineberger Comprehensive Cancer Center will receive a Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research. The $181,000 grant will be presented at the organization's 102nd Annual Meeting, to be held in Orlando, Florida, April 2-6.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Researchers verify several factors associated with increased risk of brain metastases in breast cancer patients

Nearly one-fifth of all metastatic breast cancer patients develop brain metastases and have significantly shorter overall survival than patients who do not have brain involvement. One way to improve the affected patients' survival might be to prevent the brain metastases from arising in the first place. With that in mind, researchers have been working on a predictive model that accurately identifies these high risk patients.

10 Dec 2010

Noncancerous cells from primary site appear to facilitate tumor growth: Study

The process of metastasis requires that cancer cells traveling from a primary tumor find a hospitable environment in which to implant themselves and grow. A new study from Massachusetts General Hospital (MGH) Cancer Center researchers finds that circulating tumor cells prepare this environment by bringing along from their original site noncancerous cells that support tumor growth. The report has been published online in PNAS Early Edition.

1 Dec 2010

Anti-cancer drug smuggled using a nanocarrier past protective blood-brain barrier into brain tumours

Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier - a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.

18 Nov 2010

Effective treatment for brain cancer in daffodils

When looking for new ways to treat aggressive brain cancers, an international team of scientists turned a new leaf and "discovered" the lowly daffodil. A new research study published in the November 2010 print issue of The FASEB Journal (http://www.fasebj.org) offers hope that a natural compound found in daffodil bulbs, called narciclasine, may be a powerful therapeutic against biologically aggressive forms of human brain cancers.

2 Nov 2010

Frameless radiosurgery can treat most sensitive regions of brain: Study

While four in 10 clinicians use frameless radiosurgery exclusively to treat cranial indications, user data collected at the 5th International Conference of the Novalis Circle, held last month in Munich, Germany, shows that there are still significant opportunities to increase utilization of the effective treatment approach.

20 Jul 2010

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL.

7 Jun 2010

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

27 May 2010

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

New research by scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors.

10 May 2010